Patients with severe hepatic impairment (Child Pugh C) should have their dose reduced from 1.250 mg/day to 750 mg/day (HER2 positive metastatic breast cancer indication) or from 1.500 mg/day to 1.000 mg/day (hormone receptor positive, HER2 positive breast cancer indication). Here, ERBB2 is linked to breast cancer.